Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BEBT-260
- Development stage
- Phase 1
- Lead developer
- BeBetter Med
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BEBT-260 is an orally bioavailable small molecule inhibitor of Extracellular Signal-Regulated Kinase 1 and 2 (ERK1/2), developed by Guangzhou Bibet Pharmaceutical Technology. As the terminal component of the Mitogen-Activated Protein Kinase (MAPK) signaling pathway, ERK1/2 is a critical mediator of cell growth and survival, often hyperactivated in tumors with RAS or BRAF mutations. By inhibiting ERK1/2, BEBT-260 aims to block downstream signaling that promotes cell proliferation and survival, potentially overcoming resistance to upstream MAPK pathway inhibitors such as BRAF and MEK inhibitors. The drug is currently being evaluated in Phase 1 clinical trials for the treatment of patients with advanced solid tumors.
02
Targets
CHEK1 (Checkpoint kinase 1)MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on BEBT-260.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BEBT-260.